BIOMAT Database Logo BIOMAT Database Logo

Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) reduces infection-related mortality after allogeneic T-cell depleted BMT. 1991

T De Witte, and A Gratwohl, and N Van der Lely, and A Bacigalupo, and A C Stern, and B Speck, and A Schattenberg, and C Nissen, and E Gluckman, and W E Fibbe
University Hospital Nijmegen, The Netherlands.

UI MeSH Term Description Entries
D007155 Immunologic Factors Biologically active substances whose activities affect or play a role in the functioning of the immune system. Biological Response Modifier,Biomodulator,Immune Factor,Immunological Factor,Immunomodulator,Immunomodulators,Biological Response Modifiers,Biomodulators,Factors, Immunologic,Immune Factors,Immunological Factors,Modifiers, Biological Response,Response Modifiers, Biological,Factor, Immune,Factor, Immunological,Factors, Immune,Factors, Immunological,Modifier, Biological Response,Response Modifier, Biological
D007239 Infections Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases. Infection,Infection and Infestation,Infections and Infestations,Infestation and Infection,Infestations and Infections
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008212 Lymphocyte Depletion Immunosuppression by reduction of circulating lymphocytes or by T-cell depletion of bone marrow. The former may be accomplished in vivo by thoracic duct drainage or administration of antilymphocyte serum. The latter is performed ex vivo on bone marrow before its transplantation. Depletion, Lymphocyte
D009503 Neutropenia A decrease in the number of NEUTROPHILS found in the blood. Neutropenias
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005060 Europe The continent north of AFRICA, west of ASIA and east of the ATLANTIC OCEAN. Northern Europe,Southern Europe,Western Europe
D006085 Graft Survival The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host. Graft Survivals,Survival, Graft,Survivals, Graft

Related Publications

T De Witte, and A Gratwohl, and N Van der Lely, and A Bacigalupo, and A C Stern, and B Speck, and A Schattenberg, and C Nissen, and E Gluckman, and W E Fibbe
Myelokathexis treated with recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF).
February 1992, British journal of haematology,
T De Witte, and A Gratwohl, and N Van der Lely, and A Bacigalupo, and A C Stern, and B Speck, and A Schattenberg, and C Nissen, and E Gluckman, and W E Fibbe
Prolonged administration of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) after T-cell-depleted allogeneic bone marrow transplantation.
August 1993, Transplantation proceedings,
T De Witte, and A Gratwohl, and N Van der Lely, and A Bacigalupo, and A C Stern, and B Speck, and A Schattenberg, and C Nissen, and E Gluckman, and W E Fibbe
Recombinant human granulocyte macrophage colony-stimulating factor (rhGM-CSF) induces human macrophage production of transforming growth factor-alpha.
January 1991, Cellular and molecular biology,
T De Witte, and A Gratwohl, and N Van der Lely, and A Bacigalupo, and A C Stern, and B Speck, and A Schattenberg, and C Nissen, and E Gluckman, and W E Fibbe
Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) following autologous marrow transplantation in man.
August 1988, Behring Institute Mitteilungen,
T De Witte, and A Gratwohl, and N Van der Lely, and A Bacigalupo, and A C Stern, and B Speck, and A Schattenberg, and C Nissen, and E Gluckman, and W E Fibbe
Serum granulocyte colony-stimulating factor (G-CSF) levels after allogeneic T cell-depleted marrow transplantation.
June 1995, Bone marrow transplantation,
T De Witte, and A Gratwohl, and N Van der Lely, and A Bacigalupo, and A C Stern, and B Speck, and A Schattenberg, and C Nissen, and E Gluckman, and W E Fibbe
The effects of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) on human osteoblast-like cells.
April 1989, Biochemical and biophysical research communications,
T De Witte, and A Gratwohl, and N Van der Lely, and A Bacigalupo, and A C Stern, and B Speck, and A Schattenberg, and C Nissen, and E Gluckman, and W E Fibbe
Recovery of carbimazole-induced agranulocytosis following recombinant granulocyte-macrophage colony stimulating factor (rhGM-CSF) administration.
January 1993, Haematologica,
T De Witte, and A Gratwohl, and N Van der Lely, and A Bacigalupo, and A C Stern, and B Speck, and A Schattenberg, and C Nissen, and E Gluckman, and W E Fibbe
Sustained response in Felty's syndrome to prolonged administration of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF).
June 1995, The American journal of medicine,
T De Witte, and A Gratwohl, and N Van der Lely, and A Bacigalupo, and A C Stern, and B Speck, and A Schattenberg, and C Nissen, and E Gluckman, and W E Fibbe
Recombinant human granulocyte-macrophage colony stimulating factor (rh GM-CSF) after bone marrow transplantation.
August 1988, Behring Institute Mitteilungen,
T De Witte, and A Gratwohl, and N Van der Lely, and A Bacigalupo, and A C Stern, and B Speck, and A Schattenberg, and C Nissen, and E Gluckman, and W E Fibbe
Recombinant human granulocyte-macrophage colony stimulating factor (rHuGM-CSF) in cyclic neutropenia.
January 1991, Haematologica,
Copied contents to your clipboard!